News FDA Approves Shorter Infusion Time for MS Therapy Ocrevus FDA Approves Shorter Infusion Time for MS Therapy Ocrevus by Marta Figueiredo, PhD | December 15, 2020 Share this article: Share article via email Copy article link The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion time to a two-hour session from the previously approved 3.5 hours. This may ease Ocrevusā administration burden for patients and have a positive impact on healthcare resources. āMore than 170,000 people with MS have been treated with Ocrevus ā the only approved B-cell therapy with a twice-yearly dosing schedule ā and it is the most prescribed MS medicine in the U.S.,ā Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in a press release. A subsidiary of Roche, Genentech is the developer of Ocrevus. āWe constantly strive to improve the experience that patients and their physicians have with our medicines, and we believe people with relapsing and primary progressive MS will find the shorter two-hour Ocrevus infusion time to be more convenient,ā Garraway said. The approval comes nearly eight months after the agency acceptedĀ for review Genentechās application, and follows a similar decision in the European Union. Ocrevus is an anti-CD20 monoclonal antibody that works by targeting mature B-cells, a type of immune cell that drives the inflammation that damages the nervous system in MS. It is approved inĀ the U.S. to treat relapsing forms of MS (including relapsing-remitting MS and active secondary progressive MS) as well as primary progressive MS. Ocrevus also is approved in Europe. Ocrevusā dosing schedule involves two 300 mg infusions, given two weeks apart, followed by 600 mg infusions every six months. As per the conventional infusion time, the therapy is typically administered over 3.5 hours. However, the whole process usually takes about 5.5ā6 hours, as it also includes a premedication and infusion setup that can take up to an hour, and a post-infusion observation period for another hour. The approval of the shorter infusion time was based on positive data from the ENSEMBLE PLUSĀ Phase 3 clinical trial (NCT03085810), which is evaluating the safety and effectiveness of the shorter, two-hour Ocrevus infusion against the conventional 3.5 hours in people with early stage relapsing-remitting MS. Participants received the first two 300 mg infusions over the typical 3.5 hours, after which they were assigned randomly to receive either the shorter infusion or the standard infusion for the subsequent 600 mg doses. The trialās main goal was to compare the frequency and severity of infusion-related reactions (IRRs) ā adverse side effects that occur during or within a day of the infusion ā between groups after the first 600 mg infusion. (IRRs are the most common side effect associated with Ocrevus treatment.) Results showed that the shorter infusionās safety profile was consistent with that of the conventional infusion. Specifically, the frequency of IRRs was comparable between participants who received the two-hour Ocrevus infusion (24.6%) and those given the therapy on its longer, standard infusion schedule (23.1%). In addition, most of these reactions were mild-to-moderate in both groups, and more than 98% resolved without complications. There were no reports of serious, life-threatening, or fatal IRRs and no participant discontinued treatment due to such reactions. No new safety concerns were identified. Other safety and efficacy measures also are being evaluated in the trial, which is expected to conclude in 2024. Print This Page About the Author Marta Figueiredo, PhD Marta holds a biology degree, a masterās in evolutionary and developmental biology, and a PhD in biomedical sciences from the University of Lisbon, Portugal. She was awarded a research scholarship and a PhD scholarship, and her research focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development. She also previously worked as an assistant professor of an annual one-week embryology course at the University of Lisbonās Faculty of Medicine. Tags FDA approval, Genentech, Ocrevus, Roche
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program